Aptevo Therapeutics Inc. (APVO)
After hours:
| Previous Close | 0.9890 |
| Open | 1.0100 |
| Bid | 1.1000 x 300 |
| Ask | 1.1400 x 400 |
| Day's Range | 1.0000 - 1.1400 |
| 52 Week Range | 0.6700 - 80.9600 |
| Volume | |
| Avg. Volume | 873,917 |
| Market Cap | 3.989M |
| Beta (5Y Monthly) | 4.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -67.0700 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.25 |
ACCESSWIREAptevo Therapeutics Announces Closing of $4.6 Million Public Offering
SEATTLE, WA / ACCESSWIRE / April 15, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, ...
- ACCESSWIRE
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
SEATTLE, WA / ACCESSWIRE / April 11, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, ...
- ACCESSWIRE
Aptevo Therapeutics Provides Pipeline Update
Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained stable disease diagnosis has now successfully transitioned to a higher dose level, accessing the potential for greater clinical benefit in the ...
